Delivery Order SPE2DB22D3004-SPE2DB25FRV75
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a $13,555.21 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 200 mg/1.14 mL pen injectors. This competitively awarded, non-set-aside contract is scheduled for completion by September 9, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contract vehicle supporting federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,699.54 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on September 5, 2025, with completion scheduled for September 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a $55,018.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on June 18, 2025, with completion targeted for June 20, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $7,112.21 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed price order represents a single delivery transaction under AmerisourceBergen's larger contract vehicle with DLA. The contract was executed on September 8, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,797.68 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on June 4, 2025, with completion scheduled for June 5, 2025. This non-set-aside, firm fixed-price delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order valued at $17,474.93 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 15, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and inflammatory conditions, including...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,573.96 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL quantity). This non-competitive, firm fixed-price delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a $13,125.80 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRV75Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,537.88 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 6, 2025. This is a firm fixed price, non-set-aside contract issued as a child order under AmerisourceBergen's larger pharmaceutical prime vendor agreement with DLA. The contract specifies performance at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical procurement through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for the Defense Logistics Agency's medical supply chain, providing brand-name and generic medications, vaccines, and specialized medical supplies to support military and veteran healthcare systems globally. Dupixent (dupilumab) is a prescription biologic medication commonly used to treat moderate to severe atopic dermatitis, asthma, and other allergic conditions, making this procurement consistent with the company's role as a comprehensive pharmaceutical vendor for federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 8/5/25 |